|
|
Evaluation and research progress of varicella-zoster virus vaccines |
YI Xing-Xu 1, GAN Lin1, CHEN Jing-Xian1,2, WANG Ming-Li1 |
1. Department of Microbiology, Anhui Medical University, Hefei 230032, China;2. Department of Pathology and Cell Biology, Columbia University, New York 10032, USA |
|
|
Abstract Varicellazoster virus (VZV), or human herpes virus type 3, is a member of the Herpesviridae family. VZV causes varicella (chickenpox) as primary infection which is a highly contagious epidemic disease globally. VZV reactivation from latency results in herpes zoster (shingle) which is a painful skin disease. Japan and the United States started to vaccinate all children in 1987 and 1995 respectively, which has reduced varicellarelated morbidity and mortality significantly. However, adverse events following administration of vaccine occur occasionally including secondary transmission and breakthrough infections. The research for safer VZV vaccine has been progressing with foreseeable advances.
|
Received: 26 March 2014
Published: 25 December 2014
|
Corresponding Authors:
WANG Ming-Li
|
|
|
|
|
|
|